SuperworthCOMPASS Pathways price to book ratio CMPS
Market value divided by the book value of the company's net assets, since 2022.
- Today, Oct 23, 2026
- 18.3×
- 5-year median
- 2.2×
- Against its 5-year history
- 94th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 1.2× to 24.9×
- Peer median
- 2.8×
COMPASS Pathways' price to book ratio is 18.3× as of Oct 23, 2026.
That is above its 5-year median of 2.2×, higher than on 94% of days in the last 5 years.
Over that time it ranged from 1.2× in May 2022 to 24.9× in Sep 2026.
The median for 10 large drugmakers of a similar size is 2.8×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 18.3× | 4.3× | 24.9× |
| 2025 | 17.1× | 1.2× | 17.2× |
| 2024 | 1.4× | 1.4× | 3.3× |
| 2023 | 2.1× | 1.3× | 2.8× |
| 2022 | 1.8× | 1.2× | 3.8× |
Against its peers
Companies in Drug Manufacturers - General nearest COMPASS Pathways' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| CMPSCOMPASS Pathways | 18.3× |
| PAHCPhibro Animal Health | 4.1× |
| ANABAnaptysbio | 138× |
| PCRXPacira BioSciences | 2.2× |
| ANIPANI Pharmaceuticals | 2.8× |
| OMEROmeros | n/m |
| HRMYHarmony Biosciences | 2.1× |
| AMPHAmphastar Pharmaceuticals | 1.4× |
| PBHPrestige Consumer Healthcare | 1.2× |
| NRIXNurix Therapeutics | 2.9× |
| ABUSArbutus Biopharma | 3.2× |
| Peer median | 2.8× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on COMPASS Pathways
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.